Thus, exploiting specific inhibition of ERK1/2 signalling and apoptotic priming in BRAF-mutant cells coupled with the pro-survival bias towards MCL1 could afford a large therapeutic window and further improve patient outcomes in melanoma. Here, MCL1 is linked to melanoma.